drugset
drugset / Trial / NCT01028729

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01028729 ↗

Phase 4 Unknown 120 enrolled Simcere Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This single arm study will assess the safety and efficacy of Endostar combined with chemotherapy (Gemcitabine plus Platinum-based chemotherapy) followed by Endostar maintenance therapy in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).

Timeline

Start
2009-09
Primary completion
2011-07
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 7.5 mg/m2 Intravenous
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous

Indications

non-small cell lung carcinoma